Iupac Name: | N-(2,6-Dimethylphenyl)-N-[2-[4-(1,2,4-oxadiazol-3-yl)anilino]-2-oxoethyl]-1,1-dioxothiane-4-carboxamide |
Width: | 200px |
Tradename: | Amenalief |
Legal Status: | Rx-only |
Cas Number: | 841301-32-4 |
Atc Prefix: | J05 |
Atc Suffix: | AX26 |
Pubchem: | 11397521 |
Chemspiderid: | 9572421 |
Unii: | 94X46KW4AE |
Drugbank: | 11701 |
Kegg: | D10564 |
Synonyms: | ASP-2151, ASP2151 |
C: | 24 |
H: | 26 |
N: | 4 |
O: | 5 |
S: | 1 |
Stdinchi: | 1S/C24H26N4O5S/c1-16-4-3-5-17(2)22(16)28(24(30)19-10-12-34(31,32)13-11-19)14-21(29)26-20-8-6-18(7-9-20)23-25-15-33-27-23/h3-9,15,19H,10-14H2,1-2H3,(H,26,29) |
Stdinchikey: | MNHNIVNAFBSLLX-UHFFFAOYSA-N |
Smiles: | Cc1cccc(C)c1N(CC(=O)Nc1ccc(-c2ncon2)cc1)C(=O)C1CCS(=O)(=O)CC1 |
Amenamevir (trade name Amenalief) is an antiviral drug used for the treatment of shingles (herpes zoster).
It acts as an inhibitor of the zoster virus's helicase–primase complex.[1] [2] Amenamevir was approved in Japan for the treatment of shingles in 2017.[3]